Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-19
2006-09-19
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S523000
Reexamination Certificate
active
07109191
ABSTRACT:
The present invention relates to novel benzazepinone derivatives, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and αvβ5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
REFERENCES:
patent: 6232308 (2001-05-01), Askew
patent: 6825188 (2004-11-01), Callahan et al.
patent: WO 98/14192 (1998-04-01), None
patent: WO 00/46215 (2000-08-01), None
patent: WO 00/48603 (2000-08-01), None
Coleman Paul J.
Duggan Mark E.
Hutchinson John H.
Meissner Robert S.
Wang Jiabing
Kifle Bruck
Shatynski Patricia A.
LandOfFree
Benzazepinone alpha vintegrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzazepinone alpha vintegrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzazepinone alpha vintegrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3524801